NEW YORK — Oncore Pharma said today that it has partnered with Dutch medical testing firm BodyCheck to commercialize the ColonSentry colorectal cancer test in Belgium, the Netherlands, and Luxembourg in a deal valued at $61.8 million.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?Login Now.
Don't have a 360Dx or GenomeWeb account?Register for Free.
This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.
This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.